Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces First Quarter 2015 Financial Results

San Francisco, CA (May 8, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the first quarter ended March 31, 2015 and provided updates on its programs. Development Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. Some of the highlights include: The pivotal field trial of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, continues to enroll well and the Company expects to report topline results on this program in the second half of this year. The Company has completed …

Continue Reading

Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of Fever in Horses

Randomized, Blinded, Placebo-Controlled Phase 2 Study Meets Its Primary Endpoint. San Francisco, CA (March 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses. This study, which is the equivalent of a Phase 2 study, was a randomized, blinded, placebo-controlled, crossover study that enrolled 31 adult horses. The primary endpoint was improvement or resolution of fever. In the first treatment period, the response rate was 66.7% in the KIND-012 group vs. 12.5% …

Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results

San Francisco, CA (March 12, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1:30 p.m. Pacific KindredBio today announced its fourth quarter financial results and provided updates on its programs. Development Updates KindredBio continues to build and advance its pipeline, including biologics, and now has over 20 programs across multiple product candidates and indications. Some of the key programs are highlighted below. The pivotal field trial of SentiKind, a KCNQ potassium channel agonist, for post-operative pain in dogs is currently enrolling patients …

Continue Reading

KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 12, 2015 SAN FRANCISCO, California. (March 3, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Continue Reading

KindredBio to Announce Third Quarter 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2014 SAN FRANCISCO, California. (November 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November 13, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 32324288. The call …

Continue Reading

Kindred Biosciences Announces Second Quarter 2014 Financial Results

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific “It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President and Chief Executive Officer of KindredBio. “We currently anticipate the topline results from our pivotal study of CereKin shortly. The fact that we completed the entire study from start to finish in only 12 months, and on budget, is a testament to the quality and …

Continue Reading

Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study

San Francisco, CA (May 12, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, KindredBio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).

Continue Reading